Fusarium Infections in Critically Ill Patients

Seminars in Respiratory and Critical Care Medicine

Volumn 25, Issue 2, 2004, Pages 159-169

  Lionakis, Michail S ^a   Kontoyiannis, Dimitrios P ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Fusarium; Immunocompromised host; Invasive fusariosis; Leukemia; Pneumonia

Indexed keywords

ALLOGENIC BONE MARROW TRANSPLANTATION; ASPERGILLOSIS; CLINICAL FEATURE; CRITICAL ILLNESS; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; FUSARIOSIS; FUSARIUM; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; MORTALITY; MYCOSIS; NONHUMAN; OPPORTUNISTIC INFECTION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 2142814328     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-824900     Document Type: Review

References (106)

1. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34:909-917
2. Anaissie EJ, Bodey GP, Rinaldi MG. Emerging fungal pathogens. Eur J Clin Microbiol Infect Dis 1989;8:323-330
3. Kontoyiannis DP, Bodey GP. Invasive aspergillosis in 2002: an update. Eur J Clin Microbiol Infect Dis 2002;21:161-172
4. Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997;90:999-1008
5. Torres HA, Kontoyiannis DP. Hyalohyphomycoses (other than Aspergillosis and Penicilliosis). In: Dismukes WE, Pappas PG, Sobel JD, eds. Oxford Textbook of Clinical Mycology. 1st ed. New York: Oxford University Press; 2003: 252-270
6. Anaissie E, Kantarjian H, Ro J, et al. The emerging role of Fusarium infections in patients with cancer. Medicine (Baltimore) 1988;67:77-83
7. Girmenia C, Pagano L, Corvatta L, Mele L, del Favero A, Martino P. The epidemiology of fusariosis in patients with haematological diseases. Gimema Infection Programme. Br J Haematol 2000;111:272-276
8. Martino P, Gastaldi R, Raccah R, Girmenia C. Clinical patterns of Fusarium infections in immunocompromised patients. J Infect 1994;28(suppl 1):7-15
9. Nelson PE, Dignani MC, Anaissie EJ. Taxonomy, biology, and clinical aspects of Fusarium species. Clin Microbiol Rev 1994;7:479-504
10. Pontón J, Ruchel R, Clemons KV, et al. Emerging pathogens. Med Mycol 2000;38(suppl 1):S225-S236
11. Walsh TJ, Groll AH. Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century. Transpl Infect Dis 1999;1:247-261
12. Rabodonirina M, Piens MA, Monier MF, Gueho E, Fiere D, Mojon M. Fusarium infections in immunocompromised patients: case reports and literature review. Eur J Clin Microbiol Infect Dis 1994;13:152-161
13. Mayayo E, Pujol I, Guarro J. Experimental pathogenicity of four opportunist Fusarium species in a murine model. J Med Microbiol 1999;48:363-366
14. Cho CT, Vats TS, Lowman JT, Brandsberg JW, Tosh FE. Fusarium solani infection during treatment for acute leukemia. J Pediatr 1973;83:1028-1031
15. Groll AH, Walsh TJ. Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect 2001;7(suppl 2): S8-S24
16. Richardson SE, Bannatyne RM, Summerbell RC, Milliken J, Gold R, Weitzman SS. Disseminated fusarial infection in the immunocompromised host. Rev Infect Dis 1988;10: 1171-1181
17. Anaissie E. Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin Infect Dis 1992;14(suppl 1):S43-S53
18. Perfect JR, Schell WA. The new fungal opportunists are coming. Clin Infect Dis 1996;22(suppl 2):S112-S118
19. Costa AR, Valente NY, Criado PR, Pires MC, Vasconcellos C. Invasive hyalohyphomycosis due to Fusarium solani in a patient with acute lymphocytic leukemia. Int J Dermatol 2000;39:717-718
20. Freidank H. Hyalohyphomycoses due to Fusarium spp.: two case reports and review of the literature. Mycoses 1995;38:69-74
21. Minor RL Jr, Pfaller MA, Gingrich RD, Burns LJ. Disseminated Fusarium infections in patients following bone marrow transplantation. Bone Marrow Transplant 1989;4: 653-658
22. Guarro J, Gene J. Opportunistic fusarial infections in humans. Eur J Clin Microbiol Infect Dis 1995;14:741-754
23. Musa MO, Al Eisa A, Halim M, et al. The spectrum of Fusarium infection in immunocompromised patients with haematological malignancies and in non-immunocompromised patients: a single institution experience over 10 years. Br J Haematol 2000;108:544-548
24. Raad II, Hachem R. Treatment of central venous catheter-related fungemia due to Fusarium oxysporum. Clin Infect Dis 1995;20:709-711
25. Wheeler MS, McGinnis MR, Schell WA, Walker DH. Fusarium infection in burned patients. Am J Clin Pathol 1981;75:304-311
26. Girmenia C, Arcese W, Micozzi A, Martino P, Bianco P, Morace G. Onychomycosis as a possible origin of disseminated Fusarium solani infection in a patient with severe aplastic anemia. Clin Infect Dis 1992;14:1167.
27. Gupta AK, Baran R, Summerbell RC. Fusarium infections of the skin. Curr Opin Infect Dis 2000;13:121-128
28. Nuovo MA, Simmonds JE, Chacho MS, McKitrick JC. Fusarium solani osteomyelitis with probable nosocomial spread. Am J Clin Pathol 1988;90:738-741
29. Anaissie EJ, Kuchar RT, Rex JH, et al. Fusariosis associated with pathogenic Fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections. Clin Infect Dis 2001;33: 1871-1878
30. Raad I, Tarrand J, Hanna H, et al. Epidemiology, molecular mycology, and environmental sources of Fusarium infection in patients with cancer. Infect Control Hosp Epidemiol 2002;23:532-537
31. Clemons KV, Calich VL, Burger E, et al. Pathogenesis, I: Interactions of host cells and fungi. Med Mycol 2000;38:99-111
32. Latge JP. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 1999;12:310-350
33. Rinehart JJ, Balcerzak SP, Sagone AL, LoBuglio AF. Effects of corticosteroids on human monocyte function. J Clin Invest 1974;54:1337-1343
34. Nucci M, Anaissie E, Queiroz-TeUes F, et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer 2003;98:315-319
35. Kontoyiannis DP, Bodey GP, Hanna H, et al. Outcome determinants of fusariosis in a tertiary care cancer center: the impact of neutrophil recovery. Leuk Lymphoma 2004;45: 141-143
36. Sampathkumar P, Paya CV. Fusarium infection after solid-organ transplantation. Clin Infect Dis 2001;32:1237-1240
37. Patel R, Paya CV. Infections in solid-organ transplant recipients. Clin Microbiol Rev 1997;10:86-124
38. Cohen MS, Isturiz RE, Malech HL, et al. Fungal infection in chronic granulomatous disease. The importance of the phagocyte in defense against fungi. Am J Med 1981;71:59-66
39. Girmenia C, Iori AP, Boecklin F, et al. Fusarium infections in patients with severe aplastic anemia: review and implications for management. Haematologica 1999;84:114-118
40. Torres HA, Bodey GP, Rolston KVI, Kantarjian HM, Raad II, Kontoyiannis DP. Infections in patients with aplastic anemia: experience at a tertiary care cancer center. Cancer 2003;98:86-93
41. Etzel RA. Mycotoxins. JAMA 2002;287:425-427
42. Rosenstein Y, Kretschmer RR, Lafarge-Frayssinet C. Effect of Fusarium toxins, T2-toxin and diacetoxyscirpenol on murine T-independent immune responses. Immunology 1981;44:555-560
43. Pitt JI. Toxigenic fungi: which are important? Med Mycol 2000;38(suppl 1):S17-S22
44. Sugiura Y, Sugita-Kouishi Y, Kumagai S, Reiss E. Experimental murine hyalohyphomycosis with soil-derived isolates of Fusarium solani. Med Mycol 2003;41:241-247
45. Sudhir K, MacGregor JS, DeMarco T, et al. Cyclosporine impairs release of endothelium-derived relaxing factors in epicardial and resistance coronary arteries. Circulation 1994; 90:3018-3023
46. Kiryu H, Yoshida S, Suenaga Y, Asahi M. Invasion and survival of Fusarium solani in the dexamethasone-treated cornea of rabbits. J Med Vet Mycol 1991;29:395-406
47. El-Ani AS. Disseminated infection caused by Fusarium solani in a patient with aplastic anemia. N Y State J Med 1990;90:609-610
48. Segal BH, Walsh TJ, Liu JM, Wilson JD, Kwon-Chung KJ. Invasive infection with Fusarium chlamydosporum in a patient with aplastic anemia. J Clin Microbiol 1998;36:1772-1776
49. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000;30:851-856
50. Liu K, Howell DN, Perfect JR, Schell WA. Morphologic criteria for the preliminary identification of Fusarium, Paecilomyces, and Acremonium species by histopathology. Am J Clin Pathol 1998;109:45-54
51. Hayden RT, Isotalo PA, Parrett T, et al. In situ hybridization for the differentiation of Aspergillus, Fusarium, and Pseudallescheria species in tissue section. Diagn Mol Pathol 2003;12:21-26
52. Van Burik JA, Myerson D, Schreckhise RW, Bowden RA. Panfungal PCR assay for detection of fungal infection in human blood specimens. J Clin Microbiol 1998;36:1169-1175
53. Walsh TJ, Francesconi A, Kasai M, Chanock SJ. PCR and single-strand conformational polymorphism for recognition of medically important opportunistic fungi. J Clin Microbiol 1995;33:3216-3220
54. Hennequin C, Abachin E, Symoens F, et al. Identification of Fusarium species involved in human infections by 28S rRNA gene sequencing. J Clin Microbiol 1999;37:3586-3589
55. Kovacicova G, Spanik S, Kunova A, et al. Prospective study of fungaemia in a single cancer institution over a 10-y period: aetiology, risk factors, consumption of antifungals and outcome in 140 patients. Scand J Infect Dis 2001;33:367-374
56. Trabasso P, Vigorito AC, De Souza CA, Moretti-Branchini ML. Invasive fungal infection in hematopoietic stem cell transplant recipients at a Brazilian university hospital. Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL: 2001: Abstract K-1248
57. Farina C, Vailati F, Manisco A, Goglio A. Fungaemia survey: a 10-year experience in Bergamo, Italy. Mycoses 1999;42:543-548
58. Kontoyiannis DP, Sumoza D, Tarrand J, Bodey GP, Storey R, Raad II. Significance of aspergillemia in patients with cancer: a 10-year study. Clin Infect Dis 2000;31:188-189
59. Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin Infect Dis 2002;35:909-920
60. Bodey GP, Boktour M, Mays S, et al. Skin lesions associated with Fusarium infection. J Am Acad Dermatol 2002;47:659-666
61. Arikan S, Lozano-Chiu M, Paetznick V, Nangia S, Rex JH. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species. J Clin Microbiol 1999;37:3946-3951
62. Anaissie EJ, Hachem R, Legrand C, Legenne P, Nelson P, Bodey GP. Lack of activity of amphotericin B in systemic murine fusarial infection. J Infect Dis 1992;165:1155-1157
63. Guarro J, Pujol I, Mayayo E. In vitro and in vivo experimental activities of antifungal agents against Fusarium solani. Antimicrob Agents Chemother 1999;43:1256-1257
64. Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, Rex JH. In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results. Antimicrob Agents Chemother 2002;46:3298-3300
65. Kontoyiannis DP, Lewis RE. Antifungal drug resistance of pathogenic fungi. Lancet 2002;359:1135-1144
66. Koizumi T, Kubo K, Kaneki T, et al. Pharmacokinetic evaluation of amphotericin B in lung tissue: lung lymph distribution after intravenous injection and airspace distribution after aerosolization and inhalation of amphotericin B. Antimicrob Agents Chemother 1998;42:1597-1600
67. Mohammedi I, Gachot B, Grossin M, Marche C, Wolff M, Vachon F. Overwhelming myocarditis due to Fusarium oxysporum following bone marrow transplantation. Scand J Infect Dis 1995;27:643-644
68. Ortoneda M, Capilla J, Pastor FJ, Pujol I, Guarro J. Efficacy of liposomal amphotericin B in treatment of systemic murine fusariosis. Antimicrob Agents Chemother 2002;46:2273-2275
69. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998;26:1383-1396
70. Lewis RE, Wiederhold NP. The solubility ceiling: a possible rationale for continuous infusion amphotericin B therapy? Clin Infect Dis 2003;37:871-872
71. Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob Agents Chemother 2002;46:834-840
72. Reuben A, Anaissie E, Nelson PE, et al. Antifungal susceptibility of 44 clinical isolates of Fusarium species determined by using a broth microdilution method. Antimicrob Agents Chemother 1989;33:1647-1649
73. Hirose H, Terasaki H, Awaya S, Yasuma T. Treatment of fungal corneal ulcers with amphotericin B ointment. Am J Ophthalmol 1997;124:836-838
74. Barret JP, Ramzy PI, Heggers JP, Villareal C, Herndon DN, Desai MH. Topical nystatin powder in severe burns: a new treatment for angioinvasive fungal infections refractory to other topical and systemic agents. Burns 1999;25:505-508
75. Johnson EM, Szekely A, Warnock DW. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother 1998;42:741-745
76. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998;36:2950-2956
77. Espinel-Ingroff A, Boyle K, Sheehan DJ. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 2001;150:101-115
78. Fothergill AW, Rinaldi MG, Schwocho LR, Ohya S. Comparison of the investigational azole CS-758 (R-120758) to amphotericin B, fluconazole, and itraconazole against 250 mould fungi. Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL: 2001: Abstract J-822
79. Huczko E, Minassian B, Washo T, Bonner D, Fung-Tomc J. In vitro activity of ravuconazole against Zygomycetes, Scedosporium and Fusarium isolates. Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL: 2001: Abstract J-810
80. Lozano-Chiu M, Arikan S, Paetznick VL, Anaissie EJ, Loebenberg D, Rex JH. Treatment of murine fusariosis with SCH 56592. Antimicrob Agents Chemother 1999;43:589-591
81. Marco F, Pfaller MA, Messer SA, Jones RN. In vitro activity of a new triazole antifungal agent, SCH 56592, against clinical isolates of filamentous fungi. Mycopathologia 1998;141:73-77
82. Pfaller MA, Messer SA, Hollis RJ, Jones RN, and the Sentry Participants Group Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B tested against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from the SENTRY antimicrobial surveillance program, 2000. Antimicrob Agents Chemother 2002;46:1032-1037
83. Reyes GH, Long L, Hossain M, Ghannoum MA. Evaluation of voriconazole efficacy in the treatment of murine fusariosis. Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL: 2001: Abstract J-1604
84. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003;36:1122-1131
85. Consigny S, Dhedin N, Datry A, Choquet S, Leblond V, Chosidow O. Successful voriconazole treatment of disseminated fusarium infection in an immunocompromised patient. Clin Infect Dis 2003;37:311-313
86. Hachem R, Raad II, Afif C, et al. An open, non-comparative multicenter study to evaluate efficacy and safety of posaconazole (SCH 56592) in the treatment of invasive fungal infections refractory to or intolerant of standard therapy. Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario, Canada: 2000: Abstract J-1109
87. Johnson EM, Szekely A, Warnock DW. In vitro activity of Syn-2869, a novel triazole agent, against emerging and less common mold pathogens. Antimicrob Agents Chemother 1999;43:1260-1263
88. Capilla J, Ortoneda M, Pastor FJ, Guarro J. In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi. Antimicrob Agents Chemother 2001;45:2635-2637
89. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother 2001;45:327-330
90. Del Poeta M, Schell WA, Perfect JR. In vitro antifungal activity of pneumocandin L-743, 872 against a variety of clinically important molds. Antimicrob Agents Chemother 1997;41:1835-1836
91. Pfaller MA, Marco F, Messer SA, Jones RN. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis 1998;30:251-255
92. Tawara S, Ikeda F, Maki K, et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000;44:57-62
93. Apostolidis J, Bouzani M, Platsouka E, et al. Resolution of fungemia due to Fusarium species in a patient with acute leukemia treated with caspofungin. Clin Infect Dis 2003; 36:1349-1350
94. Li RK, Rinaldi MG. In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole. Antimicrob Agents Chemother 1999;43:1401-1405
95. Lionakis MS, Lewis RE, Samonis G, Kontoyiannis DP. Pentamidine is active in vitro against Fusarium species. Antimicrob Agents Chemother 2003;47:3252-3259
96. Petranyi G, Meingassner JG, Mieth H. Activity of terbinafine in experimental fungal infections of laboratory animals. Antimicrob Agents Chemother 1987;31:1558-1561
97. Del Poeta M, Schell WA, Dykstra CC, et al. In vitro antifungal activities of a series of dication-substituted carbazoles, furans, and benzimidazoles. Antimicrob Agents Chemother 1998;42:2503-2510
98. Merz WG, Karp JE, Hoagland M, Jett-Goheen M, Junkins JM, Hood AF. Diagnosis and successful treatment of fusariosis in the compromised host. J Infect Dis 1988;158: 1046-1055
99. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002;46:245-247
100. Clancy CJ, Nguyen MH. The combination of amphotericin B and azithromycin as a potential new therapeutic approach to fusariosis. J Antimicrob Chemother 1998;41:127-130
101. Stern GA. In vitro antibiotic synergism against ocular fungal isolates. Am J Ophthalmol 1978;86:359-367
102. Farmaki E, Roilides E. Immunotherapy in patients with systemic mycoses: a promising adjunct. BioDrugs 2001;15: 207-214
103. Rodriguez-Adrian LJ, Grazziutti ML, Rex JH, Anaissie EJ. The potential role of cytokine therapy for fungal infections in patients with cancer: is recovery from neutropenia all that is needed? Clin Infect Dis 1998;26:1270-1278
104. Roilides E, Maloukou A, Gil-Lamaignere C, Winn RM, Panteliadis C, Walsh TJ. Differential effects of interleukin 15 on hyphal damage of filamentous fungi induced by human neutrophils. Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL: 2001: Abstract J-468
105. Winn RM, Maloukou A, Gil-Lamaignere C, Panteliadis C, Roilides E. The Eurofung Network. Interferon-gamma and granulocyte-macrophage colony stimulating factor enhance hyphal damage of Aspergillus and Fusarium spp by human neutrophils. Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL: 2001: Abstract J-134
106. Heinz T, Perfect J, Schell W, Ritter E, Ruff G, Serafin D. Soft-tissue fungal infections: surgical management of 12 immunocompromised patients. Plast Reconstr Surg 1996; 97:1391-1399